NCT02930694

A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants

A Randomized, Open-label, 2-Way Crossover, Parallel-group Study in Healthy Male and Female Subjects to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary purpose of the study is to investigate the plasma pharmacokinetics and bioavailability (BA) of a single dose of a solid dose formulation with 2 different strengths of JNJ-54175446 (50 milligram \[mg\] and 100 mg capsules) relative to the suspension of JNJ-54175446 under fasting conditions.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	JNJ-54175446 (capsule)	Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.
DRUG	JNJ-54175446 (suspension)	Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.

Timeline

• Start date: 2016-10-01
• Primary completion: 2016-12-01
• Completion: 2016-12-01
• First posted: 2016-10-12
• Last updated: 2017-02-16

Locations

1 site across 1 country: United States